Demetri GD, Paz-Ares L, Farago AF, et al. Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive (NTRK-fp) Tumors: Pooled Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. ESMO 2018, abstract LBA17. ,Lassen UN, Albert CM, Kummar S, et al. Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach. ESMO 2018, abstract 409O.
Checkpointremmer-geïnduceerde inflammatoire artritis ook na stoppen immuuntherapie
apr 2020 | Artritis, Dermato-oncologie, Immuuntherapie, Longoncologie